23andMe Holding Co. - ME Price-to-Projected Revenue Ratio

Corporate emblem and logo of 23andMe Inc (ME)

23andMe Holding Co. combines retail DNA testing with B2B pharmaceutical partnerships to minimize risk. The forward P/S value on the GURU.Markets chart illustrates the current trend, where the metric is fixed at 0.10. The company generates revenue through subscriptions and the sale of genetic kits, while focusing on drug R&D and the stabilization of its software.

23andMe Holding Co - ME Market Cap to Future Revenue Ratio (period 07/04/2022 - 04/05/2025)

Comprehensive metric breakdowns and analytics for 23andme.com (ME)

- current price and projected stock value:
Initial company analysis:ME (23andMe Inc.)
Product sample of 23andMe Holding Co.

Investing in 23andMe Holding Co. (ME) requires a rigorous filter of fundamental metrics to verify the asset's market value. The business's forward P/S ratio compares current market capitalization with expected sales volumes, allowing for an assessment of the company's valuation adequacy against a systemic decline in demand for genetic tests and a loss of customer trust, which is critical for determining the viability of the issuer's capital.

Who 23andMe Holding Co. competes with

Forward P/S Multiple A (agilent.com)|Quest Corp (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS - Forward P/S Multiple|RVTY (Revvity) - Forward Price-to-Revenue Multiple|Bio-Rad - Forward Price to Sales|Price-to-Projected Revenue Ratio anbio.com|Forward P/S Multiple Sotera Health Company|Price-to-Projected Revenue Ratio QuidelOrtho (QDEL)|OPK - Market Cap to Future Revenue Ratio|caredx.com - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Maravai LifeSciences Corp (MRVI)|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Price-to-Projected Revenue Ratio|OSUR: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple XGN|MDXH: Forward Price to Sales|Price-to-Projected Revenue Ratio Lucid Diagnostics Inc. (LUCD)|Price-to-Projected Revenue Ratio PRE (Prenetics Global Limited)|Forward P/S Multiple IMDX (Insight Molecular Diagnostics Inc)|Price to Expected Revenue Ratio TRIB (Trinity Biotech Corp)|PRPH - Price-to-Projected Revenue Ratio|Ainos (AIMD) - Forward Price-to-Revenue Multiple|CoDx (CODX) - Price-to-Projected Revenue Ratio|HSCS (Heart Test Labs) - Price-to-Projected Revenue Ratio|BMRA (Biomerica, Inc.) - Forward P/S Multiple|CDIO (Cardio Diagnostics) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Onconetix Corp (ONCO)|VRAX (Virax Biolabs Group Limited) - Forward Price to Sales|Forward P/S Multiple BJDX (Bluejay Diagnostics Corp)|Aspira Women's Health - Price-to-Projected Revenue Ratio|AXDX - Price-to-Projected Revenue Ratio|Projected Price to Revenue Centogene NV (CNTG)|ENZ (Enzo Biochem) - Forward Price-to-Revenue Multiple|fresh2.co (FRES) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Genetic Technologies Limited|Forward P/S Multiple Psychemedics Inc